First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after progression on prior EGFR-TKI treatment - ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback